



# **Q3 Investor Presentation**

November 2019

### **Important Notice**

This presentation as well as any information communicated in connection therewith (the "Presentation") contains information regarding TeamViewer AG (the "Company") and its subsidiaries (the Company, together with its subsidiaries, "TeamViewer"). It is being provided for informational purposes only and should not be relied on for any purpose and may not be redistributed, reproduced, published, or passed on to any other person or used in whole or in part for any other purpose.

Certain statements in this presentation may constitute forward looking statements. These statements are based on assumptions that are believed to be reasonable at the time they are made, and are subject to significant risks and uncertainties, including, but not limited to, those risks and uncertainties described in TeamViewer's disclosures. You should not rely on these forward-looking statements as predictions of future events and we undertake no obligation to update or revise these statements. Our actual results may differ materially and adversely from any forward-looking statements discussed in these statements due to several factors, including without limitation, risks from macroeconomic developments, external fraud, lack of innovation capabilities, inadequate data security and changes in competition levels.

This presentation may include supplemental financial measures-not clearly defined in the applicable financial reporting framework-that are or may be alternative performance measures (non-IFRS measures). TeamViewer's financial position, financial performance and cash flows should not be assessed solely based on these alternative supplemental financial measures. Under no circumstances do they replace the performance indicators presented in the consolidated financial statements and calculated in accordance with the applicable financial reporting framework. The calculation by other companies that report or describe similarly titled alternative performance measures may vary despite the use of the same or similar terminology.

The Company undertakes no obligation, and does not expect to publicly update, or publicly revise, any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to it or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements referred to above and contained elsewhere in this Presentation.



### Introduction To TeamViewer



- Net revenue retention rate 103% 2019 (3)
- with >1,000 routers across 81 locations
- Multiple levers for growth

- 1. A device which reported any activity type within 12 months
- 2. 9M 2019; growth YoY
- 3. LTM Q3 2019; gross profit margin excluding D&A and non-recurring COGS; Net revenue retention rate = 1 net value churn expansion); gross value churn as billings lost from customers that had an invoice in LTM-1 but not in LTM
- 4. FY 2018; CLTV, the expected customer lifetime value, defined as (annual recurring billings (ARB) per customer \* gross margin) / gross value churn; CAC, the customer acquisition cost, defined as sales & marketing costs / # new customers
- 5. Illustrative pre-tax operating cash flow defined as cash EBITDA capex change in net working capital; conversion defined as illustrative pre-tax operating cash flow / cash EBITDA



### Business Update: We Are On Track To Deliver On Our Commitment





Continuous Growth Momentum

- Q3 shows 63% YoY billings growth
- 103% NRR 2019 provides clear visibility for future growth
- >430k subscriptions in total reached end of Q3 2019

Successful Enterprise Launch

- Enterprise customers exceeding 10k ACV grew by 60% YoY
- Net increase of 72 customers exceeding 10k compared to previous quarter



Geographic Expansion

- ✓ +41% 9M 2019 YOY growth in EMEA
- Continued penetration in Americas (+60% 9M billings YoY growth)
- Continued investments and sales force expansion, particularly in APAC



### Use Case Innovation

- Important product updates, including Pilot 2.0
- Setting up R&D office in Greece has started

#### Sustained exceptional Profitability and Cash flows


- 10% points margin increase vs. Q3 2018 / 3% points margin increase vs. 9M 2018
- Relatively stable cost base on absolute level allows for scale effects
- ✓ FCF Conversion of 92%




### **Continuous Growth in Enterprise Segment**



### Customers With ACV<sup>(1)</sup>Above €10k (any product)






- Pharmaceuticals: €252k (Renewal)
- Automotive: €114k
  (Upsell)




1. ACV: Annual Contract Value

### **Overview of Key Performance Indicators – Q3 2019**













































### Q3 2019 Regional Billings Update



### Cash EBITDA 9M Q3 2019

#### Illustrative Cash EBITDA 9M 2019 (€m)

FYE, 31-Dec	9M 2018A	9M 2019A	Q3 2018A	Q3 2019A	
Billings	155	224	51	83	
Cost of Sales	<b>(16)</b>	(17)	<b>(6)</b>	<b>(6)</b>	Scaling of customer support and infrastructure cost for
% of Billings	10%	8%	11%	8%	Router & Server plus IFRS 16 impact
Gross Margin	90%	92%	89%	92%	
Sales	<b>(20)</b>	<b>(28)</b>	<b>(7)</b>	<b>(10)</b>	Efficient GTM model with highly efficient sales force
% of Billings	13%	13%	14%	12%	
Marketing	(12)	<b>(16)</b>	(4)	<b>(5)</b>	Very low CAC driven by Virality and strong Brand
% of Billings	8%	7%	8%	6%	
<b>R&amp;D</b>	<b>(15)</b>	<b>(21)</b>	<b>(5)</b>	<b>(7)</b>	Customer-centric and scalable product development
% of Billings	10%	9%	11%	8%	
<b>G&amp;A</b> <sup>(1)</sup>	(14)	<b>(23)</b>	<b>(5)</b>	<b>(9)</b>	Continued Investments in infrastructure and security
% of Billings	9%	10%	10%	11%	
Cash EBITDA	78	120	24	46	
% Margin	50%	53%	46%	56%	

1. G&A includes other income, other expenses and bad debt expenses



### **Free Cash Flow**

#### Illustrative FCF (€m)

	Q3 2018A	Q3 2019A
Cash EBITDA	23.6	46.0
Change in Net Working Capital	(0.5)	2.0
Сарех	(3.4)	(0.2)*
Pre-Tax FCF	19.7	47.8
% Cash Conversion	83%	104%
	9M 2018A	9M 2019A
Cash EBITDA	9M 2018A 77.7	9M 2019A 119.6
<b>Cash EBITDA</b> Change in Net Working Capital		
	77.7	119.6
Change in Net Working Capital	<b>77.7</b> 2.3	<b>119.6</b> (1.8)

Capitalised operating leases from IFRS 16 amount to ~€1 in Q3 2019

Capex for FY 2019 expected to amount to €10-15m compared to €11m in FY 2018

2020 Capex broadly in line with 2019. Thereafter mid-single digit amount.

\*NAL capex (€1.3m) not yet included



### Leverage

#### Overview of Current Capital Structure (€m)

	FY 18	LTM Q3 19
Cash And Cash Equivalents	(81)	(27)
Financial Debt	676	621
Net Financial Debt	595	595
x Net Debt / Cash EBITDA	4.9 x	3.7x

Refinancing in September with 613m nominal debt (USD, EUR and GBP) and 4.2% weighted interest

Capitalised operating leases from IFRS 16 amount to ~€8m in 2019

Clear deleveraging target to ~3.0x Net Debt / Cash EBITDA by FYE 2019


Aiming to reduce leverage to <2.0x by 2020



### **Deferred Revenue**

#### Deferred Revenue (€m)

FYE, 31-Dec	2016A	2017A	2018A	2018 9M	2019 9M
Billings	177	185	230	155	224
∆ Deferred Revenue – Perpetual	(74)	(11)	92	56	96
∆ Deferred Revenue – Subscription	(8)	(30)	(64)	(37)	(35)
∆ Deferred Revenue – Unallocated	(4)	(5)	0	0	0
Revenues	92	138	258	175	283



FY 2016 FY 2017 FY 2018 9M 2018 9M 2019

- Billings reflect invoiced amounts in any given period
- For IFRS purposes billings are recognized as revenue over time
- Historical perpetual licenses were recognized over 3 and 4 years vs. 12months rolling for subscription licenses
- Q3 2019: Higher revenues than billings in Q3 and 9M due to significant releases of old perpetual licenses that overcompensates addition to deferred revenue from subscription billings
- Revenue in 2019 will be significantly higher than billings due to release of perpetual deferred revenue; Full-year guidance is €386 – 391m revenues
- As the transition to subscription was fully completed in Q3 2018 and the vast majority of perpetual revenues is recognized by year-end 2020, the effect will reverse and billings will exceed revenue in the medium term (revenue expected to be ~90% of billings in the medium term)



### **Specific Accounting Topics**

Specific Accounting topics (€m)


	Q3 2019A	9M 2019A
IFRS 2	(26)	(27)
IPO-related charges	(8)	(8)
IPO employee bonus payment	(7)	(7)
Other IPO related cost	(1)	(1)
GDPR projects	(0)	(1)
Other non-recurring items	(4)	(7)
Total	(38)	(43)
Deferred tax income (interest carry forward)	59	59

- IFRS 2 charge relates to incentive structure put in place and fully financed by selling shareholder
- No dilution and no cash impact
- Counter-position directly booked into equity
- For more details, see IPO prospectus

#### • IPO-related charges:


- One-off bonus paid to all employees and thus eliminated for Cash EBITDA; cash impact
- Other IPO cost: one-off cost that are not reimbursed by the selling shareholder






1. Based on the mid-point of the FY2019 guidance, i.e. €315m Billings FY2019





### FY 2019 KPI Guidance Fully Confirmed



## Appendix





### **Reconciliation From Management Key Metrics To IFRS**

Consolidated Statement of Comprehensive Income Q3 2019, in €m

	Management View Adjusted P&L	Deferred Revenue	+	D&A	+	Specific Non-recurring Adjustments	Accounting View IFRS P&L
Billings / Revenue	83	19					102
Cost Of Sales	(6)			(6)		(0)	(13)
Gross Profit Contribution	76 / (92% of Billings)						89 / (88% of Revenue)
Other Income	8			_		-	8
Sales	(10) / (12% of Billings)			(1)		(3)	(14) / (14% of Revenue)
Marketing	(5) / (6% of Billings)			(0)		(1)	(6) / (6% of Revenue)
R&D	(7) / (8% of Billings)			(1)		(3)	(10) / (10% of Revenue)
G&A	(12) / (14% of Billings)			(1)		(31) (2)	(44) / (43% of Revenue)
Other Expenses <sup>(1)</sup>	(5)			_		_	(5)
Cash EBITDA	46/ (56% of Billings)						
D&A	(9)						
Cash EBIT / Operating Profit	37 / (45% of Billings)						18 / (18% of Revenue)
D&A							9
EBITDA							27 / (27% of Revenue)
	·						`'

1. Including Bad debt expense

2. Mainly relates to IFRS 2 adjustment as outlined on page 15

### **Reconciliation From Management Key Metrics To IFRS**

Consolidated Statement of Comprehensive Income 9M 2019, in €m

	Management View Adjusted P&L	Deferred Revenue	+	D&A	+	Specific Non-recurring Adjustments	Accounting View IFRS P&L
Billings / Revenue	224	59					283
Cost Of Sales	(17)			(19)		(1)	(36)
Gross Profit Contribution	207 / (92% of Billings)						247 / (87% of Revenue)
Other Income	16			_		-	16
Sales	(28) / (13% of Billings)			(3)		(3)	(35) / (12% of Revenue)
Marketing	(16) / (7% of Billings)			(1)		(1)	(17) / (6% of Revenue)
R&D	(21) / (9% of Billings)			(3)		(3)	(27) / (9% of Revenue)
G&A	(27) / (12% of Billings)			(2)		(35) (2)	(64) / (23% of Revenue)
Other Expenses <sup>(1)</sup>	(12)			_		-	(12)
Cash EBITDA	120/ (53% of Billings)						
D&A	(27)						
Cash EBIT / Operating Profit	92 / (41% of Billings)						108 / (38% of Revenue)
D&A							27
EBITDA							135 / (48% of Revenue)
	`						`'

1. Including bad debt expense

2. Mainly relates to IFRS 2 adjustment as outlined on page 15

### **Deferred Revenue**

Deferred Revenue (€m)

		For the year ended Decembe			ne months otember 30,
	2016	2017	2018	2018	2019
Perpetual - BoP	181	254	265	265	173
Perpetual - Release of Deferred Revenue	78	106	122	83	97
Perpetual - Addition of Deferred Revenue	151	117	30	27	1
Perpetual - EoP	254	265	173	209	78
Subscription - BoP	б	14	43	43	107
Subscription - Release of Deferred Revenue	18	38	136	90	187
Subscription - Addition of Deferred Revenue	26	68	200	127	222
Subscription - EoP	14	43	107	81	143
Total Deferred Revenue - BoP	186	268	309	309	281
Total Deferred Revenue - Release	96	144	258	173	284
Total Deferred Revenue - Addition	177	185	230	154	224
Total Deferred Revenue - EoP	268	309	281	290	220



### **Consolidated P&L**

Consolidated P&L (€m)						
	Q3 2019	Q3 2018	% YOY	9M 2019	9M 2018	% YOY
Revenue	102	73	39%	283	175	62%
Cost of sales	(13)	(12)	5%	(36)	(35)	5%
Gross profit / (loss)	89	61	46%	247	140	76%
Other income	8	0	>100%	16	1	>100%
R&D	(10)	(6)	70%	(27)	(17)	60%
Sales	(14)	(8)	81%	(35)	(21)	64%
Marketing	(6)	(4)	48%	(17)	(12)	40%
G&A	(44)	(6)	>100%	(64)	(18)	>100%
Other expenses	(0)	(0)	>100%	(1)	(0)	>100%
Bad debt expense	(5)	(1)	>100%	(11)	(4)	>100%
Dperating profit / (loss)	18	36	-49%	108	69	58%
Unrealised foreign exchange gains / (losses)	3	(3)	-	(1)	(16)	-91%
Realised foreign exchange gains / (losses)	(21)	(0)	>100%	(20)	(0)	>100%
Finance income	17	8	>100%	39	12	>100%
Finance costs	(37)	(17)	>100%	(77)	(54)	42%
Profit / (Loss) before taxation	(21)	23	-	49	10	>100%
Tax income / (expense)	34	(13)	-	10	(10)	_
Profit / (Loss) for the period	14	10	>100%	59	0	>100%



### **Consolidated Balance Sheet**

	September 30, 2019	December 31, 2018
Ion-current assets:		
Property, plant and equipment	12	2
Goodwill	591	584
Intangible assets	239	253
Deferred tax assets	2	0
Other non-current assets	5	1
otal non-current assets	850	840
Current assets:		
Trade receivables	9	15
Cost to obtain a contract current	0	1
Other current assets	10	3
Current tax assets	7	0
Financial assets	0	10
Cash and cash equivalents	27	80
Fotal current assets	54	108
otal assets	903	948

## Consolidated Balance Sheet (cont'd)

	September 30, 2019	December 31, 2018	
iquity:			
Issued capital	200	0	
Capital reserve	310	116	
(Accumulated losses)/retained earnings	(474)	(333)	
Foreign currency translation reserve	1	0	
otal equity	37	(217)	
Ion-current liabilities:			
Interest-bearing loans and borrowings	610	679	
Deferred revenue	7	47	
Deferred tax liabilities	0	19	
Financial liabilities	0	3	
otal non-current liabilities	617	748	
Current liabilities:			
Interest-bearing loans and borrowings	3	155	
Trade payables	8	7	
Deferred revenue	213	233	
Accrued expenses and other payables	22	14	
Current tax liabilities	0	0	
Provisions	2	1	
Financial liabilities	0	7	
otal current liabilities	249	417	
otal equity and liabilities	903	948	

### **Consolidated Statement of Cash Flows**

Consolidated Statement of Cash Flows (€m)

	For the nine ended Septe	
	2019	2018
Cash flows from operating activities:		
Profit for the period (net income/net loss)	59	0
Amortisation and depreciation	27	22
(Gain)/ loss on sale of fixed assets	(0)	0
(Increase)/decrease of provisions	1	0
Unrealised foreign exchange (gains)/losses	20	16
Non-cash share-based compensation expenses	27	1
Financial result effect	38	42
Changes in working capital	(63)	(16)
Tax expense/(income)	(10)	10
Taxation paid	(15)	(1)
Interest paid (other than borrowings)	(0)	0
let cash from operating activities	84	75



## Consolidated Statement of Cash Flows (cont'd)

Consolidated Statement of Cash Flows (€m)	For the nine months ended September 30,				
	2019	2018			
Cash flows from investing activities:					
Investments	0	0			
Capital expenditure	(8)	(8)			
Finance effects	0	0			
Net cash used in investing activities	(8)	(8)			
Cash flows from financing activities:					
Loans & borrowings	(136)	(41)			
Repayments of borrowings	(179)	(4)			
Proceeds from bank borrowings	74	0			
Payments of lease	0	(4)			
Interest paid on borrowings	(27)	(37)			
Proceeds / payments from the settlement of derivatives	0	0			
Proceeds / payments of capital contribution	0	0			
Proceeds / repayments of intercompany loans	0	0			
Proceeds / payments of intercompany interest	0	0			
Net cash from financing activities	(136)	(41)			
Net change in cash funds	(60)	25			
Other cash effects for balance sheet reconciliation <sup>1</sup>	б	(1)			
1. Including net foreign exchange difference, net change from cash risk provisioning, internal mergers and transfers					

## **Quarterly KPIs**

Quarterly KPIs for the Three Months Ended (€m)

	2016			2017			2018			2019					
	Mar-31	Jun-30	Sep-30	Dec-31	Mar-31	Jun-30	Sep-30	Dec-31	Mar-31	Jun-30	Sep-30	Dec-31	Mar-31	Jun-30	Sep-30
Revenue	20	21	24	27	30	33	36	40	47	55	73	83	87	95	102
EMEA	13	14	15	17	19	20	22	24	28	32	43	48	49	54	57
AMS	5	5	6	7	8	9	10	11	14	16	22	25	27	29	32
APAC	2	2	3	3	4	4	4	5	5	6	9	10	10	12	13
Other / reconciliation															
Billings	46	37	32	63	52	38	29	65	55	48	51	75	69	73	83
EMEA	28	20	17	40	32	21	16	44	34	25	23	47	40	40	36
AMS	13	12	11	16	15	12	9	14	15	13	20	21	21	20	36
APAC	5	5	5	6	6	5	4	7	7	10	7	7	8	13	11
Other / reconciliation															
Cash EBITDA	31	20	14	42	33	18	10	42	33	21	24	43	35	28	46
Cash EBITDA margin (in %)	67%	54%	43%	68%	64%	48%	33%	64%	61%	43%	46%	57%	51%	39%	56%

### Refinancing

New Financing in place since 09/2019

	Amount	6M Base	Margin	All-in interest
RCF	35	0.00%	2.50%	
Total loan amount	613			4.18%
o/w EUR	125	0.00%	2.50%	2.50%
o/w USD	413	2.06%	2.75%	4.81%
o/w GBP	75	0.83%	2.75%	3.56%

- 613m refinancing with 35m additional RCF facility on 27 September 2019
- Mandatory repayment of 5% starting 12/31/2020, full repayment on 26 September 2024
- EURIBOR, LIBOR (USD) and LIBOR (GPB) as base rates
- First lien USD with 1% floor, EUR and GBP with 0% floor

• Full amoritization of unexpensed transaction costs

